Eisai's Groundbreaking Dementia Drug Set To Transform Treatment In America

Japanese pharmaceutical company Eisai is working on a new dementia treatment, aiming for U.S. commercialization by fiscal 2030, according to a Sunday report by the Nikkei. The drug targets the tau protein, which is responsible for Alzheimer's disease symptoms. Eisai already markets a dementia drug in the U.S. called Leqembi, developed in collaboration with American partner Biogen. On Friday, the companies announced plans to launch Leqembi in China, making it the third country to offer the treatment after the U.S. and Japan.